The Tyrosine Hydroxylase Deficiency is also known as recessive dopa-responsive dystonia and is a rare genetic disorder. In the Tyrosine Hydroxylase Deficiency, there is lack of enzymes which are involved in converting amino acid tyrosine to L-dopa. A wide range of symptoms can be associated with the Tyrosine Hydroxylase Deficiency, and it varies from patient to patient. The most common symptoms include the uncoordinated or clumsy manner of walking (abnormal gait) and dystonia. In mild and severe cases patients may have neurological disorders.
The Tyrosine Hydroxylase Deficiency market is mainly driven by the high prevalence of neurological disorders and huge demand for diagnosis and treatment methods for rare diseases. Additionally, the increasing availability of diagnostic services for various rare diseases also fuels the growth of the market. Moreover, favorable reimbursement policies are likely to boost the market growth. On the other hand, expensive treatments for severe cases may hamper the market growth during the forecast period.
Tyrosine Hydroxylase Deficiency market is expected to register a CAGR of 6.4% during the forecast period.
Source: World Health Organization, Centers for Disease Control and Prevention, European Society of Clinical Microbiology and Infectious Diseases, U.S. National Library of Medicine, National Organization for Rare Disorders, The American Autoimmune Related Diseases Association, The International Society for Human and Animal Mycology, Expert Interview Market Research Future Analysis, Annual report, White paper, Company Presentation
The Tyrosine Hydroxylase Deficiency market is segmented on the basis of form, diagnosis, treatment, and end-user.
On the basis of form, the market is segmented into mild, moderate, and severe.
On the basis of diagnosis, the Tyrosine Hydroxylase Deficiency Market is segmented into an examination of cerebrospinal fluid, genetic testing, and others.
On the basis of treatment, the market is segmented into medication, speech therapy, and others. Medication is further segmented into anticholinergic drugs (trihexyphenidyl and amantadine).
On the basis of end-user, the market is segmented into hospitals and clinics, diagnostic centers, and others.
FIGURE 1: Tyrosine Hydroxylase Deficiency Market, by Region, 2016 (%)
Source: Centers for Disease Control and Prevention, World Health Organization, population reference bureau, Statistics Canada, StatsCan, Centers for Medicare & Medicaid Services, U.S. Census Bureau, Organization for Economic Co-operation and Development, Expert Interview, Market Research Future Analysis, Annual report, White paper, Company Presentation
Regional Analysis of the Tyrosine Hydroxylase Deficiency Market
The American Tyrosine Hydroxylase Deficiency market is segmented into two regions, namely, North America and South America. North America, being the largest market, is mainly driven by the increasing use of new and advanced methods for the diagnosis and treatment of the disease and more number of patients related to neurological disorders. Furthermore, the U.S. is the largest market in North America owing to the presence of a large number of market players manufacturing medications for the Tyrosine Hydroxylase Deficiency and the increasing awareness about risk factors and cases of the disease. Canada is expected to be the fastest growing market which is driven by the overall increasing demand for diagnostic medical devices with progress in the medical device sector. South America is expected to be the fastest growing market due to technologically advanced devices for diagnosis and the increasing demand for treatment options for various rare diseases.
The European Tyrosine Hydroxylase Deficiency market exhibits growth with an increasing emphasis on the diagnosis of heart diseases such as the Tyrosine Hydroxylase Deficiency and others. Moreover, Germany and the U.K. are the major contributors to the growth of the market. Additionally, the increasing expenditure in the healthcare industry by major countries in Europe also accelerates the growth of the market.
Asia Pacific is expected to be the fastest growing market whose growth is attributed to a huge demand for diagnostic tests and increasing focus on early diagnosis and treatment of heart diseases. Furthermore, other factors contributing to the growth of the market are lifestyle changes, the influence of western culture among the adults, and addiction to smoking. Additionally, the increasing environmental pollution and exposure to harmful chemicals also attribute to the growth of the market.
The Middle Eastern and African market for the Tyrosine Hydroxylase Deficiency exhibits a steady rise with an increase in the number of healthcare facilities providing treatment of the chronic condition and the flourishing growth of the medical device sector, especially the diagnostic devices. In the African region, the awareness about rare diseases is fueling the growth of the market.
Key Players in the Tyrosine Hydroxylase Deficiency Market
Some of the key players in this market are Fujifilm Holdings (Japan), GE Healthcare (U.S.), Siemens Healthcare(U.S.), Philips Healthcare (U.S.), Shimadzu Corporation (Japan), GeneDx (U.S), PGxHealth LLC (U.S), Abbott (U.S), GE healthcare (U.K), Medtronic (U.S.), Pfizer, Inc (U.S), Boston Scientific Corporation (U.S.), GlaxoSmithKline (U.K), Eli Lilly Company (U.S.), Taj Pharmaceuticals Ltd (India), and others.
Tyrosine Hydroxylase Deficiency is a condition where enzymes involved in converting tyrosine to L-dopa are deficient, leading to a wide range of symptoms, which can differ from person to person.
Global Tyrosine Hydroxylase Deficiency Market is expected to exhibit a strong 6.4% CAGR over the forecast period till 2027.
The growing prevalence of neurological disorders is the key driver for the Tyrosine Hydroxylase Deficiency Market.
The Americas are the largest regional market for Tyrosine Hydroxylase Deficiency.
Leading players in the Tyrosine Hydroxylase Deficiency Market include Siemens Healthcare, GE Healthcare, and Fujifilm Holdings, among others.